Pfizer's Xeljanz Approved in Japan - Analyst Blog

By
A A A

Pfizer Inc. ( PFE ) recently announced that its rheumatoid arthritis treatment, Xeljanz, gained approval in Japan. The Japanese Ministry of Health, Labor and Welfare (MHLW) approved Xeljanz for the treatment of rheumatoid arthritis in adults who have not responded adequately to existing therapies.

Xeljanz can be used in patients in whom clinical symptoms related to the disease remain even after the patients have undergone treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate.

Pfizer said that Xeljanz will be commercially launched once the National Health Insurance listing is completed. Pfizer will be promoting the product with Takeda Pharmaceutical ( TKPYY ) in Japan. Pfizer also co-promotes Enbrel in Japan with Takeda.

We note that Xeljanz gained approval in the US in early Nov 2012. Xeljanz is the first oral treatment to gain approval in a new class of medicines known as Janus kinase (JAK) inhibitors. The product represents a new treatment option for patients who respond inadequately to or are unable to tolerate methotrexate.

Pfizer currently carries a Zacks Rank #3 (Hold). Pfizer's 2013 guidance was in-line with expectations. While near-term earnings will be driven by cost cutting efforts and share repurchases, longer-term growth will depend on the success of drug development. The company's pipeline needs to deliver given the Lipitor loss of exclusivity and the upcoming loss of exclusivity on additional products in the next few years.

Currently, large-cap pharma companies like Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) look better-positioned. Both are Zacks Rank #2 (Buy) stocks.



LILLY ELI & CO (LLY): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

TAKEDA PHARMACT (TKPYY): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: LLY , NVO , PFE , TKPYY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

100%
50%
89%

Most Active by Volume

86,692,048
  • $16.82 ▼ 1.35%
66,073,054
  • $13.30 ▼ 6.27%
54,801,491
  • $14.59 ▼ 1.35%
54,305,010
  • $76.55 ▼ 3.15%
53,982,567
  • $3.42 ▼ 2.01%
53,146,472
  • $97.21 ▼ 1.60%
50,334,521
  • $99.18 ▼ 1.56%
44,049,276
  • $25.03 ▼ 0.56%
As of 10/1/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com